RU2016110925A3 - - Google Patents

Download PDF

Info

Publication number
RU2016110925A3
RU2016110925A3 RU2016110925A RU2016110925A RU2016110925A3 RU 2016110925 A3 RU2016110925 A3 RU 2016110925A3 RU 2016110925 A RU2016110925 A RU 2016110925A RU 2016110925 A RU2016110925 A RU 2016110925A RU 2016110925 A3 RU2016110925 A3 RU 2016110925A3
Authority
RU
Russia
Application number
RU2016110925A
Other languages
Russian (ru)
Other versions
RU2016110925A (ru
RU2690183C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016110925A publication Critical patent/RU2016110925A/ru
Publication of RU2016110925A3 publication Critical patent/RU2016110925A3/ru
Application granted granted Critical
Publication of RU2690183C2 publication Critical patent/RU2690183C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • External Artificial Organs (AREA)
RU2016110925A 2013-09-26 2014-09-26 Простагландин f2 альфа и его аналоги для лечения атрофического кожного рубцевания RU2690183C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361960740P 2013-09-26 2013-09-26
US61/960,740 2013-09-26
PCT/IB2014/002746 WO2015044788A1 (en) 2013-09-26 2014-09-26 Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring

Publications (3)

Publication Number Publication Date
RU2016110925A RU2016110925A (ru) 2017-11-01
RU2016110925A3 true RU2016110925A3 (enExample) 2018-07-13
RU2690183C2 RU2690183C2 (ru) 2019-05-31

Family

ID=52282772

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016110925A RU2690183C2 (ru) 2013-09-26 2014-09-26 Простагландин f2 альфа и его аналоги для лечения атрофического кожного рубцевания

Country Status (11)

Country Link
US (1) US10039770B2 (enExample)
EP (1) EP3049088B1 (enExample)
JP (1) JP6453318B2 (enExample)
KR (1) KR102221499B1 (enExample)
CN (1) CN105658221B (enExample)
AU (1) AU2014326298B2 (enExample)
BR (1) BR112016006426A2 (enExample)
CA (1) CA2924460A1 (enExample)
MX (1) MX374476B (enExample)
RU (1) RU2690183C2 (enExample)
WO (1) WO2015044788A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6659819B2 (ja) * 2015-07-09 2020-03-04 ガルデルマ・ソシエテ・アノニム 化学療法に関連する脱毛の軽減方法
CN106929477B (zh) * 2017-03-20 2020-01-10 江南大学 一株抗前列腺素F2α的特异性单克隆抗体杂交瘤细胞株WXX-2及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
RU2195889C2 (ru) * 1999-05-24 2003-01-10 Парамонов Борис Алексеевич Способ дермабразии
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP2278993A4 (en) * 2008-05-16 2012-09-12 Corthera Inc METHOD FOR PROMOTING HEALING
EP2389939A1 (en) * 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
CN102031260A (zh) * 2010-08-24 2011-04-27 苏州圣诺生物医药技术有限公司 促进皮肤伤口无疤痕愈合的siRNA及应用
EP3178465A1 (en) * 2010-12-06 2017-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
AU2012212481A1 (en) * 2011-01-31 2013-08-22 Allergan, Inc. Method of enhancing hair growth
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
WO2014179263A1 (en) * 2013-04-30 2014-11-06 Allergan, Inc. Therapeutic agents

Also Published As

Publication number Publication date
JP6453318B2 (ja) 2019-01-16
CN105658221A (zh) 2016-06-08
KR102221499B1 (ko) 2021-03-02
RU2016110925A (ru) 2017-11-01
AU2014326298A1 (en) 2016-04-07
CN105658221B (zh) 2022-05-10
MX2016003650A (es) 2016-06-24
WO2015044788A1 (en) 2015-04-02
US10039770B2 (en) 2018-08-07
EP3049088A1 (en) 2016-08-03
EP3049088B1 (en) 2021-02-17
RU2690183C2 (ru) 2019-05-31
KR20160055941A (ko) 2016-05-18
US20160228453A1 (en) 2016-08-11
AU2014326298B2 (en) 2019-07-04
MX374476B (es) 2025-03-06
JP2016531872A (ja) 2016-10-13
CA2924460A1 (en) 2015-04-02
BR112016006426A2 (pt) 2017-08-01

Similar Documents

Publication Publication Date Title
BR112015007533A2 (enExample)
BR102016010778A2 (enExample)
BR112014017733A2 (enExample)
BR112014018502A2 (enExample)
BR112014017739A2 (enExample)
BR112014019326A2 (enExample)
BR112014018480A2 (enExample)
BR112014018516A2 (enExample)
BR112016008300A2 (enExample)
BR112014020341A2 (enExample)
BR112016003714A2 (enExample)
BR112014017765A2 (enExample)
BR112014017669A2 (enExample)
BR112014021878A2 (enExample)
BR112014018468A2 (enExample)
BR112014019204A2 (enExample)
BR112015015948A2 (enExample)
BR112016004122A2 (enExample)
BR112016004050A2 (enExample)
BR112016014115A2 (enExample)
BR112014017722A2 (enExample)
BR112014017653A2 (enExample)
BR112014018578A2 (enExample)
BR112014018483A2 (enExample)
BR112014017794A2 (enExample)